Insilico Medicine has just signed a deal worth up to $2.75 billion with Eli Lilly, putting the spotlight firmly on AI-driven drug discovery.
In this episode of Companies to Watch, Dan Koh and Ryan Huang break down what Insilico Medicine actually does, why its Hong Kong IPO drew massive investor demand, and what this latest partnership means for the future of healthcare.

Singapore Unfiltered: Eh, Singlish ok for office or not?
22:33

Talk of the Town: Singapore is clean. So, why are our hawker toilets still dirty?
35:53

Breakfast Bites: Halal/Non-Halal Tray Returns: How seriously do you take them?
11:22